AYSUN FATMA AKKUŞ

Dr. AYSUN FATMA AKKUŞ

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in The Prostate
Verified
Journal Article
Open access
MHMuhammet Bekir Hacıoğlu
Muhammet Bekir Hacıoğlu
AKAhmet Küçükarda
Ahmet Küçükarda
IGivo gokmen
ivo gokmen
AGAli Fuat Gurbuz
Ali Fuat Gurbuz
MAMurat Araz
Murat Araz
BEBülent Erdoğan
Bülent Erdoğan
Objective: The Prognostic Nutritional Index (PNI), reflects the nutritional and immunological status of the patient and has been associated with outcomes in various cancers. In this study, the prognostic significance of PNI in metastatic hormone‐sensitive prostate cancer (mHSPC) and its potential role in guiding treatment decisions between abiraterone acetate and enzalutamide is investigated.Methods: Retrospective analysis was performed on 167 mHSPC patients treated between 2019 and 2024. PNI was calculated using the formula: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm³). Patients were stratified into high and low PNI groups according to a cutoff value of 49.98, determined via receiver operating characteristic (ROC) analysis. Survival outcomes, including overall survival (OS), radiographic progression‐free survival (rPFS), and PSA progression‐free survival (PSA‐PFS), were assessed. Treatment responses to abiraterone acetate and enzalutamide were compared within PNI strata.Results: Patients with PNI > 49.98 had significantly longer median OS than those with PNI ≤ 49.98 (36.6 months vs. 30.0 months, p < 0.01). Multivariate analysis identified high PNI, ECOG performance status 0–1, and absence of visceral metastasis as independent predictors of improved OS. Among patients with low PNI, those treated with enzalutamide had superior OS compared to those receiving abiraterone acetate (p = 0.004), while no significant OS difference was noted between treatments in the high PNI group (p = 0.55).Conclusion: PNI serves as a significant prognostic biomarker in mHSPC, correlating with overall survival and potentially influencing treatment efficacy between abiraterone acetate and enzalutamide. Integrating PNI into clinical practice may aid in tailoring individualized treatment options.

21 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FAFahri Akgül
Fahri Akgül
IGivo gokmen
ivo gokmen
İBİsmail Bayrakçı
İsmail Bayrakçı
DDDidem Divriklioglu
Didem Divriklioglu
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
BEBülent Erdoğan
Bülent Erdoğan
Background: The Naples Prognostic Score (NPS) is a composite inflammation–nutrition index whose prognostic value has been scarcely examined in extensive-stage small cell lung cancer (ES-SCLC). This study aimed to evaluate the prognostic significance of the NPS in this setting. Methods: A retrospective analysis was performed on 142 patients diagnosed with ES-SCLC between March 2014 and June 2024. The NPS was calculated using the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), serum albumin, and total cholesterol levels. Patients were classified into three NPS categories (0, 1–2, and 3–4), and subsequently dichotomized into low-risk (0–2) and high-risk (3–4) groups. Survival outcomes were assessed using Kaplan–Meier estimates and multivariate Cox regression models. Results: Median overall survival (OS) was significantly longer in the low-risk group compared to the high-risk group (10.3 vs. 6.3 months; p = 0.012). High NPS remained an independent predictor of reduced OS (HR: 1.45; 95% CI: 1.02–2.06; p = 0.041). The prognostic strength of the NPS was primarily driven by low LMR and hypoalbuminemia, which were individually associated with worse outcomes. Conclusions: The NPS may serve as a simple, accessible, and independent prognostic tool in ES-SCLC, potentially aiding in clinical risk stratification and treatment planning.

16 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
GÖGökhan Öztürk
Gökhan Öztürk
ETEbru Taştekin
Ebru Taştekin
CTCanberk Topuz
Canberk Topuz
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
TATayyip İlker Aydın
Tayyip İlker Aydın
AKAhmet Küçükarda
Ahmet Küçükarda
Background and Objectives: The Gustave Roussy Immune (GRIm) score, reflecting systemic inflammation and nutritional status, has emerged as a simple and reproducible prognostic biomarker in various malignancies. However, its prognostic interaction with tumor microenvironmental factors remains unclear in gastric cancer. The primary aim of this study was to evaluate the prognostic value of the GRIm score in patients with resectable gastric adenocarcinoma, while the secondary aim was to determine whether integrating the GRIm score with tumor microenvironment–related pathological markers could improve prognostic stratification. Materials and Methods: This retrospective study analyzed 188 patients with resectable gastric adenocarcinoma treated at the Trakya University Faculty of Medicine between 2007 and 2018. GRIm scores were calculated from preoperative lactate dehydrogenase (LDH), albumin, and neutrophil-to-lymphocyte ratio (NLR) values. Pathologic parameters, including programmed death-ligand 1 (PD-L1) expression (combined positive score [CPS] ≥ 1 vs. <1), tumor–stroma ratio (TSR; stromal component ≥ 50% vs. <50%), and tumor-infiltrating lymphocyte (TIL) density (CD8+ ≥ 10% vs. <10%), were evaluated on surgical specimens. Survival outcomes were assessed using Kaplan–Meier and multivariate Cox analyses. Results: The study population had a mean age of 61.8 years and was predominantly male (72.3%). Patients with low GRIm scores had significantly longer disease-free survival (DFS; 24 vs. 12 months; p = 0.004) and overall survival (OS; 32 vs. 19 months; p = 0.006). In multivariate analysis, the GRIm score remained an independent predictor for both disease-free survival (p = 0.035) and overall survival (p = 0.044). Among combined models, the GRIm–TSR classification provided the most pronounced stratification (median DFS = 35 vs. 12 months; OS = 45 vs. 19 months; p = 0.014 and 0.001, respectively), retaining independent prognostic significance (hazard ratio [HR] = 1.23; p = 0.005). Integrating GRIm with PD-L1 and TIL density also improved prognostic discrimination. Conclusions: The GRIm score is a robust and cost-effective biomarker that independently predicts disease-free survival and overall survival in resectable gastric adenocarcinoma. Its combination with microenvironmental markers—PD-L1, TIL, and TSR—captures complementary biological dimensions of tumor aggressiveness, offering an integrative and clinically feasible framework for individualized risk assessment and postoperative management. Prospective multicenter validation is warranted.

2 July 2025 in Balkan Medical Journal
Verified
Journal Article
Open access
GÖGökhan Öztürk
Gökhan Öztürk
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
MHMuhammet Bekir Hacıoğlu
Muhammet Bekir Hacıoğlu
SSSerdar Solak
Serdar Solak
EÇElif Nur Çatalbaş
Elif Nur Çatalbaş

30 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MGMurat Günaltılı
Murat Günaltılı
HBHatice Bolek
Hatice Bolek
ETEsma Kaplan Tüzün
Esma Kaplan Tüzün
SUSura Usta
Sura Usta
SESafa Can Efil
Safa Can Efil
YÜYüksel Ürün
Yüksel Ürün
Background/Objectives: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been investigated as an immunonutritional biomarker in several solid tumors; however, data in metastatic renal cell carcinoma (mRCC) remain limited. This study aimed to evaluate the prognostic significance of the pretreatment HALP score in patients with mRCC receiving first-line tyrosine kinase inhibitor (TKI) therapy. Methods: A multicenter retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. HALP was calculated as hemoglobin (g/dL) × albumin (g/dL) × lymphocyte count (×109/L)/platelet count (×109/L). Patients were categorized into HALP-low and HALP-high groups according to the cohort median HALP value. Results: A total of 1001 patients were enrolled. The median time to treatment failure (TTF) was significantly shorter in the HALP-low group than in the HALP-high group (7.43 months [95% CI 6.4–8.5] vs. 14.26 months [95% CI 12.1–16.4], p < 0.001). The median overall survival (OS) was also significantly shorter in the HALP-low group (30.19 months [95% CI 25.2–35.1] vs. 46.06 months [95% CI 38.2–53.9], p < 0.001). In multivariable analysis, a high HALP score remained independently associated with longer TTF (HR 0.73, 95% CI 0.62–0.86; p < 0.001) and OS (HR 0.69, 95% CI 0.57–0.85; p < 0.001). Conclusions: The pretreatment HALP score was independently associated with TTF and OS in patients with mRCC treated with first-line TKI therapy. These findings support the prognostic relevance of HALP in this treatment setting and warrant further evaluation of its potential role alongside established clinical risk models.

Verified
Journal Article
Open access
PDF file
AAAYSUN FATMA AKKUŞ
AYSUN FATMA AKKUŞ
GÖGökhan Öztürk
Gökhan Öztürk
ÖAÖMER FERUDUN AKKUŞ
ÖMER FERUDUN AKKUŞ
IKİlhan Kurultak
İlhan Kurultak
TATayyip İlker Aydın
Tayyip İlker Aydın
BEBülent Erdoğan
Bülent Erdoğan
Background: Anthracycline- and taxane-based chemotherapy regimens are widely used in the treatment of breast cancer; however, their effects on body composition and fluid distribution are not fully elucidated. Conventional assessment methods are often insufficient to distinguish true tissue changes from treatment-related fluid shifts. The primary objective of this study was to evaluate longitudinal changes in body composition and fluid distribution during chemotherapy in breast cancer patients using bioelectrical impedance spectroscopy. The secondary objective was to investigate the impact of anthracycline and docetaxel exposure on these changes and to identify patterns suggestive of masked sarcopenia. Methods: This prospective, single-center, longitudinal observational study was conducted between October 2024 and October 2025. Follow-up assessments at 3 and 6 months were completed by October 2025. A total of 51 female breast cancer patients undergoing systemic chemotherapy were evaluated using multifrequency bioelectrical impedance spectroscopy (BCM®). Measurements were performed at baseline, 3 months, and 6 months. Changes in total body water (TBW), extracellular water (ECW), intracellular water (ICW), extracellular-to-intracellular water ratio (E/I), lean tissue mass (LTM), adipose tissue mass (ATM), and volume status were analyzed longitudinally and according to treatment exposure. Results: The cohort consisted of 51 women (median age, 55 years), of whom 70.6% were postmenopausal, and the majority had stage II–III disease. While TBW remained stable, significant alterations in fluid distribution and body composition were observed. ECW increased, and ICW decreased, resulting in a significant rise in the E/I ratio. LTM declined significantly, particularly during the first 3 months, whereas ATM showed a gradual increase. Volume status increased progressively over time, indicating fluid accumulation. Anthracycline exposure was associated with greater reductions in LTM, while docetaxel treatment was linked to significant increases in extracellular fluid and volume, especially during the 3–6-month interval. At 6 months, a median increase of +1100 mL in volume was observed alongside a decrease in muscle mass (−1.4 kg), consistent with a pattern of masked sarcopenia. Conclusions: Chemotherapy in breast cancer patients is associated with concurrent muscle loss and fluid redistribution, which may obscure clinically relevant changes in body composition. Bioelectrical impedance spectroscopy enables differentiation between fluid and tissue compartments and provides a more accurate assessment than conventional methods. Early recognition of these changes may facilitate timely nutritional support and appropriate fluid management strategies.